Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer

Mamoru Ito, Hitoshi Kusaba, Satomi Mukaide, Junji Kishimoto, Hozumi Shimokawa, Shingo Tamura, Akitaka Makiyama, Gen Hirano, Hisanobu Oda, Tsuyoshi Shirakawa, Masato Komoda, Keita Uchino, Risa Tanaka, Kenji Mitsugi, Taito Esaki, Shuji Arita, hiroshi ariyama, Koichi Akashi, Eishi Baba

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抄録

A close correlation between early tumor shrinkage (ETS) and overall survival (OS) has been shown in antiepidermal growth factor receptor antibody-based chemotherapies for metastatic colorectal cancer (mCRC), but the clinical impact of ETS in bevacizumab-based chemotherapy has not been adequately clarified. Clinical data of mCRC patients who started initial chemotherapy without antiepidermal growth factor receptor antibody from 2005 to 2010 were retrospectively evaluated. The relative change in tumor size after 8 weeks of chemotherapy expected from the first image assessment [estimated ETS (EETS)] and the relative change in the tumor size at the nadir compared with the baseline [depth of response (DPR)] were examined. Seventy-three patients were enrolled and 61 patients were evaluable for survival by simple regression analysis. Bevacizumab-based chemotherapies were administered to 40 (66%) patients. The median EETS, DPR, progression-free survival, and OS were 16.1%, 27.2%, 8.0 months, and 19.5 months, respectively. Progression-free survival showed a positive correlation with OS (R 2 =0.429), whereas EETS and DPR were less correlated with OS (R 2 =0.0682, 0.186). EETS was well correlated with DPR (R 2 =0.659). Patients with EETS greater than 16.12% were predicted to achieve tumor shrinkage of more than 30% at the maximum response. EETS in bevacizumab-treated mCRC showed a close correlation with DPR, which suggested that EETS might be useful, indicating a favorable response in treatment with bevacizumab-based chemotherapy.

元の言語英語
ページ(範囲)1166-1173
ページ数8
ジャーナルAnti-cancer drugs
28
発行部数10
DOI
出版物ステータス出版済み - 1 1 2017

Fingerprint

Colorectal Neoplasms
Drug Therapy
Survival
Neoplasms
Growth Factor Receptors
Disease-Free Survival
Antibodies
Bevacizumab
Regression Analysis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

これを引用

Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer. / Ito, Mamoru; Kusaba, Hitoshi; Mukaide, Satomi; Kishimoto, Junji; Shimokawa, Hozumi; Tamura, Shingo; Makiyama, Akitaka; Hirano, Gen; Oda, Hisanobu; Shirakawa, Tsuyoshi; Komoda, Masato; Uchino, Keita; Tanaka, Risa; Mitsugi, Kenji; Esaki, Taito; Arita, Shuji; ariyama, hiroshi; Akashi, Koichi; Baba, Eishi.

:: Anti-cancer drugs, 巻 28, 番号 10, 01.01.2017, p. 1166-1173.

研究成果: ジャーナルへの寄稿記事

Ito, M, Kusaba, H, Mukaide, S, Kishimoto, J, Shimokawa, H, Tamura, S, Makiyama, A, Hirano, G, Oda, H, Shirakawa, T, Komoda, M, Uchino, K, Tanaka, R, Mitsugi, K, Esaki, T, Arita, S, ariyama, H, Akashi, K & Baba, E 2017, 'Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer', Anti-cancer drugs, 巻. 28, 番号 10, pp. 1166-1173. https://doi.org/10.1097/CAD.0000000000000562
Ito, Mamoru ; Kusaba, Hitoshi ; Mukaide, Satomi ; Kishimoto, Junji ; Shimokawa, Hozumi ; Tamura, Shingo ; Makiyama, Akitaka ; Hirano, Gen ; Oda, Hisanobu ; Shirakawa, Tsuyoshi ; Komoda, Masato ; Uchino, Keita ; Tanaka, Risa ; Mitsugi, Kenji ; Esaki, Taito ; Arita, Shuji ; ariyama, hiroshi ; Akashi, Koichi ; Baba, Eishi. / Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer. :: Anti-cancer drugs. 2017 ; 巻 28, 番号 10. pp. 1166-1173.
@article{f541d31613504b1ca9817548a8d58429,
title = "Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer",
abstract = "A close correlation between early tumor shrinkage (ETS) and overall survival (OS) has been shown in antiepidermal growth factor receptor antibody-based chemotherapies for metastatic colorectal cancer (mCRC), but the clinical impact of ETS in bevacizumab-based chemotherapy has not been adequately clarified. Clinical data of mCRC patients who started initial chemotherapy without antiepidermal growth factor receptor antibody from 2005 to 2010 were retrospectively evaluated. The relative change in tumor size after 8 weeks of chemotherapy expected from the first image assessment [estimated ETS (EETS)] and the relative change in the tumor size at the nadir compared with the baseline [depth of response (DPR)] were examined. Seventy-three patients were enrolled and 61 patients were evaluable for survival by simple regression analysis. Bevacizumab-based chemotherapies were administered to 40 (66{\%}) patients. The median EETS, DPR, progression-free survival, and OS were 16.1{\%}, 27.2{\%}, 8.0 months, and 19.5 months, respectively. Progression-free survival showed a positive correlation with OS (R 2 =0.429), whereas EETS and DPR were less correlated with OS (R 2 =0.0682, 0.186). EETS was well correlated with DPR (R 2 =0.659). Patients with EETS greater than 16.12{\%} were predicted to achieve tumor shrinkage of more than 30{\%} at the maximum response. EETS in bevacizumab-treated mCRC showed a close correlation with DPR, which suggested that EETS might be useful, indicating a favorable response in treatment with bevacizumab-based chemotherapy.",
author = "Mamoru Ito and Hitoshi Kusaba and Satomi Mukaide and Junji Kishimoto and Hozumi Shimokawa and Shingo Tamura and Akitaka Makiyama and Gen Hirano and Hisanobu Oda and Tsuyoshi Shirakawa and Masato Komoda and Keita Uchino and Risa Tanaka and Kenji Mitsugi and Taito Esaki and Shuji Arita and hiroshi ariyama and Koichi Akashi and Eishi Baba",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/CAD.0000000000000562",
language = "English",
volume = "28",
pages = "1166--1173",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer

AU - Ito, Mamoru

AU - Kusaba, Hitoshi

AU - Mukaide, Satomi

AU - Kishimoto, Junji

AU - Shimokawa, Hozumi

AU - Tamura, Shingo

AU - Makiyama, Akitaka

AU - Hirano, Gen

AU - Oda, Hisanobu

AU - Shirakawa, Tsuyoshi

AU - Komoda, Masato

AU - Uchino, Keita

AU - Tanaka, Risa

AU - Mitsugi, Kenji

AU - Esaki, Taito

AU - Arita, Shuji

AU - ariyama, hiroshi

AU - Akashi, Koichi

AU - Baba, Eishi

PY - 2017/1/1

Y1 - 2017/1/1

N2 - A close correlation between early tumor shrinkage (ETS) and overall survival (OS) has been shown in antiepidermal growth factor receptor antibody-based chemotherapies for metastatic colorectal cancer (mCRC), but the clinical impact of ETS in bevacizumab-based chemotherapy has not been adequately clarified. Clinical data of mCRC patients who started initial chemotherapy without antiepidermal growth factor receptor antibody from 2005 to 2010 were retrospectively evaluated. The relative change in tumor size after 8 weeks of chemotherapy expected from the first image assessment [estimated ETS (EETS)] and the relative change in the tumor size at the nadir compared with the baseline [depth of response (DPR)] were examined. Seventy-three patients were enrolled and 61 patients were evaluable for survival by simple regression analysis. Bevacizumab-based chemotherapies were administered to 40 (66%) patients. The median EETS, DPR, progression-free survival, and OS were 16.1%, 27.2%, 8.0 months, and 19.5 months, respectively. Progression-free survival showed a positive correlation with OS (R 2 =0.429), whereas EETS and DPR were less correlated with OS (R 2 =0.0682, 0.186). EETS was well correlated with DPR (R 2 =0.659). Patients with EETS greater than 16.12% were predicted to achieve tumor shrinkage of more than 30% at the maximum response. EETS in bevacizumab-treated mCRC showed a close correlation with DPR, which suggested that EETS might be useful, indicating a favorable response in treatment with bevacizumab-based chemotherapy.

AB - A close correlation between early tumor shrinkage (ETS) and overall survival (OS) has been shown in antiepidermal growth factor receptor antibody-based chemotherapies for metastatic colorectal cancer (mCRC), but the clinical impact of ETS in bevacizumab-based chemotherapy has not been adequately clarified. Clinical data of mCRC patients who started initial chemotherapy without antiepidermal growth factor receptor antibody from 2005 to 2010 were retrospectively evaluated. The relative change in tumor size after 8 weeks of chemotherapy expected from the first image assessment [estimated ETS (EETS)] and the relative change in the tumor size at the nadir compared with the baseline [depth of response (DPR)] were examined. Seventy-three patients were enrolled and 61 patients were evaluable for survival by simple regression analysis. Bevacizumab-based chemotherapies were administered to 40 (66%) patients. The median EETS, DPR, progression-free survival, and OS were 16.1%, 27.2%, 8.0 months, and 19.5 months, respectively. Progression-free survival showed a positive correlation with OS (R 2 =0.429), whereas EETS and DPR were less correlated with OS (R 2 =0.0682, 0.186). EETS was well correlated with DPR (R 2 =0.659). Patients with EETS greater than 16.12% were predicted to achieve tumor shrinkage of more than 30% at the maximum response. EETS in bevacizumab-treated mCRC showed a close correlation with DPR, which suggested that EETS might be useful, indicating a favorable response in treatment with bevacizumab-based chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85032286684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032286684&partnerID=8YFLogxK

U2 - 10.1097/CAD.0000000000000562

DO - 10.1097/CAD.0000000000000562

M3 - Article

C2 - 28906258

AN - SCOPUS:85032286684

VL - 28

SP - 1166

EP - 1173

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 10

ER -